JARDIANCE 10 10

About

JARDIANCE 10 contains Empagliflozin, an oral medication classified as a sodium-glucose co-transporter 2 (SGLT2) inhibitor. It is primarily used to improve glycemic control in adults with type 2 diabetes mellitus. Empagliflozin works by blocking the SGLT2 protein in the kidneys, which is responsible for reabsorbing glucose back into the bloodstream. By inhibiting SGLT2, it causes the kidneys to excrete more glucose in the urine, thereby lowering blood glucose levels.

Beyond its glucose-lowering effects, JARDIANCE has demonstrated significant cardiovascular and renal benefits. It is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. It also slows the progression of kidney disease in certain patient populations, making it a multifaceted treatment option.

Uses

• Improvement of glycemic control in adults with type 2 diabetes mellitus.
• Reduction of cardiovascular death risk in type 2 diabetes with established CVD.
• Reduction of hospitalization for heart failure in adults with heart failure.
• Slowing the progression of chronic kidney disease in certain patients.

Directions For Use

Take one tablet orally once daily in the morning, with or without food. Swallow the tablet whole with water.

Benefits

• Effectively lowers blood glucose levels.
• Reduces risk of major cardiovascular events.
• Provides significant renal protective benefits.
• Promotes modest weight loss.
• Low risk of hypoglycemia when used as monotherapy.
• Convenient once-daily dosing.

Side Effects

• Urinary tract infections (UTIs)
• Genital mycotic infections (e.g., yeast infections)
• Increased urination
• Thirst
• Nausea
• Dizziness
• Hypotension (low blood pressure)
• Ketoacidosis (rare but serious)
• Kidney problems (acute kidney injury)
• Fournier's gangrene (very rare)
• Back pain
• Joint pain

Safety Measures

• Alcohol - Excessive alcohol intake can increase the risk of ketoacidosis and dehydration, which are potential side effects of JARDIANCE. Limit alcohol consumption.
• Pregnancy - Not recommended during the second and third trimesters of pregnancy due to potential adverse effects on fetal kidney development.
• Breastfeeding - Not recommended during breastfeeding as it is unknown if Empagliflozin is excreted in human milk and could pose a risk to the infant.
• Liver - No dose adjustment is required for patients with hepatic impairment.
• Kidney - Not recommended for patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²) or end-stage renal disease.
• Lung - No specific contraindications or significant interactions related to lung conditions are typically noted for JARDIANCE.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.